This is a multicenter， open-label study to evluate the efficacy and safety of a novel PARP 1/2 inhibitor fluzoparib （SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer.

Fluzoparib (SHR-3162) is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) 1/2 being developed for treatment of BRCA1/2-mutant solid tumor. The tolerability, safety and PK of fluzoparib has been evaluated in Phase 1 study. An oral formulation is the focus of current development efforts.

Inclusion Criteria:

• Histologically confirmed diagnosis of high grade serous or Grade 2/3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer；
• Confirmed documented BRCA1/2 mutation;
• Received 2~4 prior chemotherapy regimens. Non-chemotherapy regimens and maintenance therapies administered as single agent treatment will not count as a chemotherapy regimen；
• Relapsed/progressive disease as confirmed by radiologic assessment；
• Have measurable disease as defined by RECIST v1.1.

Exclusion Criteria:

• Any previous treatment with a PARP inhibitor;
• Patient with any other malignancy which has been active or treated within the previous 5 years;
• Patients with symptomatic uncontrolled brain metastases;
• Patients unable to swallow orally administered medication.